A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY4060874 in Healthy Participants
Latest Information Update: 04 Dec 2024
Price :
$35 *
At a glance
- Drugs LY 4060874 (Primary) ; LY 4060874 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 04 Dec 2024 New trial record